50,000
`
` 45,000
`
` 40,000
`
` 35,000
`
` 30,000
`
`CN Market Size (Patients)
`
` 25,000
`
` 20,000
`
` 15,000
`
`ZYTIGA®
`
`
`Market Share:
`
`
`100%
`
`Monthly Patient Share & Market Size: Chemo. Naive Patients
`
`Dec CN Market Share:
`ZYTIGA 21%
`XTANDI 19%
`
`Q4Avg CN Market Share:
`ZYTIGA 21%
`XTANDI 19%
`
`
`
`90%
`
`80%
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`Patient Market Share
`
`
`
` 10,000
`
` 5,000
`
` -
`
`
`
`Oct-16
`
`Jul-16
`
`Apr-16
`
`Jan-16
`
`Oct-15
`
`Jul-15
`
`Apr-15
`
`Jan-15
`
`Oct-14
`
`Jul-14
`
`Apr-14
`
`Jan-14
`
`Oct-13
`
`Jul-13
`
`Apr-13
`
`Jan-13
`
`Zytiga
`
`Xtandi
`
`Leuprolide
`
`Bicalutamide
`
`Docetaxel
`
`CN Market Size
`
`C. Market Share/Market Growth (ZYTIGA):
`
`Market Definition:
`
`Metastatic Castrate Resistant Prostate Cancer (mCRPC)
`patients
`
`
`2016 Actual Average Monthly Treated Patients: 54,800 patients (14,100 in Chemo Refractory; 40,700 in
`Chemo Naïve)
`
`
`2016 Actual Annual Market Growth:
`
`*2016 BP Projected Avg. Monthly Treated Patients: 56,819 patients (15,312 in Chemo Refractory; 41,507 in
`Chemo Naive)
`
`3.2% (1.5% in Chemo Refractory; 3.8% in Chemo Naïve)
`
`
`
`ACTIVE 220440902v.1
`
`JANSSEN EXHIBIT 2134
`Wockhardt v. Janssen IPR2016-01582
`
`

`

`*2016 BP Projected Market Growth vs. 2015 Actual: 6.9% (10.3% in Chemo Refractory; 5.7% in Chemo
`Naive)
`
`
`Source of ZYTIGA data:
`Source of XTANDI data:
`
`IMS DDD; Symphony Health Solutions (SHS)
`SHS data based on ZYTIGA® Xponent sample to IMS
`DDD universe (sample of claims from SPP/Pharmacy to
`Payer)
`
`
`J&J Patient Assistance Foundation (JJPAF) Utilization: JJPAF donations increased over 2016 due to
`access/affordability issues. For comparison purposes,
`we applied a consistent upward adjustment factor to
`both ZYTIGA and XTANDI demand data to account for
`the increase. We do not have insight into the actual
`utilization of XTANDI’s patient assistance program.
`
`
`Veteran’s Affairs (VA) Buy-Ins:
`
`
`*Note CR/CN projected Market/Share not available for NU
`
`Year-end VA buy-ins excluded from December market
`share for both ZYTIGA and XTANDI which will be
`reflected in market shares in 2017.
`
`% Market Growth (in patients) vs. Prior Year Quarter:
`
`
`
`
`
`3Q16
`2Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`
`0.9%
`6.0%
`9.1%
`13.1%
`13.6%
`15.2%
`15.1%
`13.2%
`Total Market Growth
`4.7%
`-0.2%
`0.5%
`1.8%
`7.2%
`7.8%
`12.9%
`13.3%
`Chemo Refractory Market Growth
`-0.4%
`8.4%
`12.3%
`17.4%
`15.9%
`18.2%
`15.9%
`13.1%
`Chemo Naïve Market Growth
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December)
`
`
`4Q16
`-2.9%
`0.6%
`-4.0%
`
`
`
`
`Total ZYTIGA Share
`Chemo Refractory Share
`Chemo Naïve Share
`Total XTANDI Share
`
`
`4Q14
`31.5%
`39.4%
`28.5%
`19.0%
`
`% Market Share (in patients)
`
`2Q15
`28.1%
`37.2%
`24.7%
`23.2%
`
`3Q15
`27.4%
`39.1%
`23.4%
`24.1%
`
`1Q15
`29.9%
`39.0%
`26.4%
`20.6%
`
`4Q15
`26.6%
`40.9%
`21.9%
`23.4%
`
`1Q16
`26.1%
`40.1%
`21.4%
`24.5%
`
`2Q16
`25.2%
`39.4%
`20.3%
`25.9%
`
`3Q16
`27.0%
`43.9%
`21.0%
`24.4%
`
`4Q16
`26.7%
`44.3%
`20.7%
`22.5%
`
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December)
`
`Chemo Refractory US Market Share (in patients)
`
`4Q16
`3Q16
`2Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`
`44.3%
`43.9%
`39.4%
`40.1%
`40.9%
`39.1%
`37.2%
`39.0%
`39.4%
`ZYTIGA
`33.6%
`35.1%
`38.5%
`37.0%
`35.6%
`39.2%
`41.8%
`42.5%
`43.9%
`XTANDI
`10.6%
`10.2%
`9.6%
`10.6%
`9.4%
`8.9%
`8.3%
`8.5%
`8.3%
`Jevtana
`24.2%
`23.5%
`25.1%
`24.9%
`26.7%
`25.3%
`25.2%
`22.5%
`21.0%
`All Other
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December).
`Share including all competitors exceeds 100% as a result of products being used in combination therapy.
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`50%
`45%
`40%
`35%
`30%
`25%
`20%
`15%
`10%
`5%
`0%
`
`Monthly Patient Share: Chemo. Refractory Market
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16
`
`Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`
`Zytiga
`
`Jevtana
`
`Xtandi
`
`All Other
`
`40%
`
`10%
`
`35%
`
`27%
`
`40%
`
`10%
`
`37%
`
`26%
`
`41%
`
`11%
`
`36%
`
`24%
`
`40%
`
`11%
`
`37%
`
`25%
`
`39%
`
`10%
`
`39%
`
`25%
`
`39%
`
`9%
`
`38%
`
`25%
`
`
`40%
`
`10%
`
`38%
`
`25%
`
`43%
`
`10%
`
`36%
`
`23%
`
`45%
`
`10%
`
`34%
`
`24%
`
`44%
`
`11%
`
`35%
`
`23%
`
`43%
`
`10%
`
`34%
`
`25%
`
`44%
`
`11%
`
`33%
`
`25%
`
`45%
`
`11%
`
`34%
`
`23%
`
`
`
`
`
`
`
`Chemo Naïve US Market Share (in patients)
`
`
`3Q16
`2Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`3Q14
`
`21.0%
`20.3%
`21.4%
`21.9%
`23.4%
`24.7%
`26.4%
`28.5%
`29.7%
`ZYTIGA
`20.5%
`21.6%
`20.3%
`19.4%
`18.9%
`16.3%
`12.4%
`9.6%
`6.8%
`XTANDI
`16.0%
`15.5%
`16.0%
`16.0%
`15.3%
`16.4%
`17.4%
`19.2%
`19.8%
`Bicalutamide
`9.2%
`9.6%
`9.4%
`10.1%
`9.1%
`8.2%
`8.0%
`10.0%
`7.7%
`Docetaxel
`42.8%
`43.6%
`44.6%
`45.6%
`47.3%
`49.4%
`52.1%
`50.2%
`54.1%
`All Other
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December)
`Share including all competitors exceeds 100% as a result of products being used in combination therapy
`
`4Q16
`20.7%
`18.7%
`16.2%
`9.1%
`43.8%
`
`ACTIVE 220440902v.1
`
`

`

`50%
`
`45%
`
`40%
`
`35%
`
`30%
`
`25%
`
`20%
`
`15%
`
`10%
`
`5%
`
`0%
`
`Monthly Patient Share: Chemo. Naive Market
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`
`Zytiga
`
`Xtandi
`
`Bicalutamide
`
`Docetaxel
`
`All Other
`
`21%
`
`19%
`
`17%
`
`10%
`
`45%
`
`22%
`
`20%
`
`16%
`
`9%
`
`45%
`
`22%
`
`20%
`
`16%
`
`9%
`
`45%
`
`21%
`
`21%
`
`16%
`
`10%
`
`44%
`
`21%
`
`22%
`
`16%
`
`10%
`
`43%
`
`20%
`
`22%
`
`15%
`
`10%
`
`44%
`
`20%
`
`21%
`
`15%
`
`9%
`
`44%
`
`21%
`
`21%
`
`16%
`
`10%
`
`43%
`
`20%
`
`21%
`
`16%
`
`9%
`
`43%
`
`22%
`
`20%
`
`16%
`
`9%
`
`43%
`
`21%
`
`19%
`
`17%
`
`9%
`
`43%
`
`20%
`
`18%
`
`16%
`
`9%
`
`44%
`
`21%
`
`19%
`
`16%
`
`9%
`
`44%
`
`
`Full Year Historical Average Share (in patients):
`
`
`
`
`
`Total ZYTIGA
` ZYTIGA CR
` ZYTIGA CN
`Total XTANDI
` XTANDI CR
` XTANDI CN
`
`2012
`25.4%
`62.3%
`11.9%
`2.7%
`8.7%
`0.5%
`
`2013
`30.6%
`54.7%
`21.4%
`10.5%
`29.7%
`3.3%
`
`2014
`33.0%
`44.2%
`28.7%
`16.0%
`40.2%
`6.7%
`
`2015
`28.0%
`39.1%
`24.1%
`22.8%
`39.8%
`16.7%
`
`2016
`26.3%
`42.0%
`20.9%
`24.3%
`36.0%
`20.2%
`
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`D. Supplemental Information (ZYTIGA):
`
`
`Monthly Average Patient Share: Total Chemo Refractory and Chemo Naïve
`
`50%
`
`45%
`
`40%
`
`35%
`
`30%
`
`25%
`
`20%
`
`15%
`
`10%
`
`5%
`
`0%
`
`Total Chemo Naive/Chemo Refractory Patient Market Share
`
`27%
`
`23%
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16
`
`Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`
`ZYTIGA share
`
`Xtandi share
`
`26%
`
`23%
`
`26%
`
`24%
`
`27%
`
`24%
`
`26%
`
`25%
`
`25%
`
`26%
`
`25%
`
`26%
`
`25%
`
`26%
`
`27%
`
`25%
`
`27%
`
`24%
`
`27%
`
`24%
`
`27%
`
`23%
`
`26%
`
`22%
`
`27%
`
`23%
`
`
`
`ZYTIGA
`
`Launch to Date Demand $
`4Q16 Gross Demand $
`
`Chemo
`Refractory %
`44.1%
`42.3%
`
`Chemo
`Naïve %
`55.9%
`57.7%
`
`
`
`ZYTIGA
`
`Oncologist % Urologist %
`
`Launch to Date Demand TRx
`2015 Gross Demand TRx
`4Q16 Gross Demand TRx
`
`92.1%
`89.4%
`90.5%
`
`7.9%
`10.6%
`9.5%
`
`
`
`XTANDI
`2015 Gross Demand TRx
`4Q16 Gross Demand TRx
`
`Oncologist %
`82.2%
`78.0%
`
`Urologist%
`17.8%
`22.0%
`
`
`
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`
`ZYTIGA launch-to-date TRx and NRx (SPP/Retail):
`
` ZYTIGA experienced a Q4 Year over Year SPP/Retail TRx decline of 11% based on the latest IMS
`Xponent data.
`
`Nov-16
`
`Sep-16
`
`Jul-16
`
`May-16
`
`Mar-16
`
`Jan-16
`
`Nov-15
`
`Sep-15
`
`Jul-15
`
`May-15
`
`Mar-15
`
`Jan-15
`
`Nov-14
`
`Sep-14
`
`Jul-14
`
`May-14
`
`Mar-14
`
`Jan-14
`
`Nov-13
`
`Sep-13
`
`Jul-13
`
`May-13
`
`Mar-13
`
`Jan-13
`
`Nov-12
`
`Sep-12
`
`Jul-12
`
`May-12
`
`Mar-12
`
`Jan-12
`
`Nov-11
`
`Sep-11
`
`Jul-11
`
`May-11
`
`NRx
`
`TRx
`
`
`
`1,800
`
`1,600
`
`1,400
`
`1,200
`
`1,000
`
`800
`
`600
`
`400
`
`200
`
`0
`
`
`
`
`
`
`
`2015
`
`4Q15
`
`3Q16
`
`4Q16*
`
` 1,375
` 411
`
` 1,462
`1,548
`1,584
`TRx
` 435
`450
`472
`NRx
`*Chart reflects data through the fourth week of December
`
`Source: IMS Xponent weekly data (updated through week ending 12/23).
`Note: TRx & NRx trends are a measure of our retail business and do not include VA/Other channels or
`free product dispensed through JJPAF.
`
`Growth
`vs. 4Q15
`-11.2%
`-8.7%
`
`Growth
`vs. 3Q16
`-6.0%
`-5.6%
`
`
`
`ACTIVE 220440902v.1
`
`

`

`
`
`
`E. Line of Therapy Model (ZYTIGA):
`
`In 2016, ZYTIGA transitioned to Line of Therapy model, for business performance reporting and metrics.
`
`
`CN/CR to mCRPC Market Bridge
`
` 13,680
`
` 7,050
`
` 3,380
`
` 54,800
`
` 30,690
`
`CN/CR
`Market
`
`remove
`mHSPC
`
`remove
`nmCRPC
`
`mCRPC
`Market
`
`remove
`palliative
`care and
`drug holidays
`
` 60,000
`
` 50,000
`
` 40,000
`
` 30,000
`
` 20,000
`
` 10,000
`
` -
`
`Average Monthly patients
`
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`Market Share:
`
`Monthly Patient Share & Market Size: Total mCRPC Patients
`
`mCRPC Market Size (Patients)
`
`35,000
`
`30,000
`
`25,000
`
`20,000
`
`15,000
`
`10,000
`
`5,000
`
`0
`
`Dec mCRPC Market Share:
`ZYTIGA 35%
`XTANDI 32%
`
`Q4Avg mCRPC Market Share:
`ZYTIGA 34%
`XTANDI 31%
`
`
`
`Jan-13 Apr-13 Jul-13 Oct-13 Jan-14 Apr-14 Jul-14 Oct-14 Jan-15 Apr-15 Jul-15 Oct-15 Jan-16 Apr-16 Jul-16 Oct-16
`
`100%
`
`90%
`
`80%
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`Patient Market Share
`
`
`
`Zytiga
`
`Xtandi
`
`Docetaxel
`
`Other Chemo
`
`Other Hormone
`
`mCRPC Market Size
`
`
`
`Market Definition:
`
`
`2016 Actual Average Monthly Treated Patients*:
`*Does not include spontaneous use
`
`
`2016 Actual Annual Market Growth:
`
`Metastatic Castrate Resistant Prostate Cancer (mCRPC)
`patients
`
`30,659 mCRPC patients
`o 15,067 in 1st line mCRPC
`o 7,213 in 2nd line mCRPC
`o 5,770 in 3rd+ line mCRPC
`o 2,610 in line 0 mCRPC (not treated with
`chemo or advanced oral therapy like ZYTIGA
`or XTANDI)
`
`7.7% in mCPRC
`o 9.1% in 1st line mCRPC
`o 1.0% in 2nd line mCRPC
`o 11.7% in 3rd+ line mCRPC
`
`
`2016 NU Projected Average Monthly Treated Patients: 30,560 CRPC patients
`o 14,880 in 1st line mCRPC
`o 7,660 in 2nd line mCRPC
`o 5,400 in 3rd+ line mCRPC
`o 2,620 in line 0 mCRPC (not treated with
`chemo or advanced oral therapy like ZYTIGA
`or XTANDI)
`
`
`
`ACTIVE 220440902v.1
`
`

`

`2016 NU Projected Market Growth vs. 2015 Actual: 7.4% in mCRPC (YoY growth)
`o 7.6% in 1st line mCRPC
`o 7.2% in 2nd line mCRPC
`o 9.5% in 3rd+ line mCRPC
`
`
`Source of ZYTIGA data:
`Source of XTANDI data:
`
`IMS DDD; Symphony Health Solutions (SHS)
`SHS data based on ZYTIGA Xponent sample to IMS DDD
`universe (sample of claims from SPP/Pharmacy to
`Payer)
`
`
`J&J Patient Assistance Foundation (JJPAF) Utilization: JJPAF donations increased over 2016 due to
`access/affordability issues. For comparison purposes,
`we applied a consistent upward adjustment factor to
`both ZYTIGA and XTANDI demand data to account for
`the increase. We do not have insight into the actual
`utilization of XTANDI’s patient assistance program.
`
`
`Veteran’s Affairs (VA) Buy-Ins:
`
`
`
`
`
`Year-end VA buy-ins excluded from December market
`share for both ZYTIGA and XTANDI which will be
`reflected in market shares in 2017.
`
`% Market Growth (in patients) vs. Prior Year Quarter:
`
`3Q16
`2Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`
`8.3%
`10.1%
`11.3%
`10.9%
`13.2%
`16.4%
`19.8%
`22.6%
`Total Market Growth (mCRPC lines 1-4+)
`10.4%
`10.7%
`9.3%
`10.4%
`13.8%
`19.2%
`25.2%
`26.4%
`1st line mCRPC Market Growth
`1.1%
`3.7%
`7.3%
`14.6%
`15.1%
`16.5%
`19.4%
`21.7%
`2nd line mCRPC Market Growth
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December)
`
`% Market Share (in patients)
`
`4Q16
`1.3%
`5.4%
`-7.8%
`
`
`
`2Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`
`31.9%
`33.3%
`34.1%
`35.5%
`36.3%
`38.2%
`39.1%
`Total Zytiga Share (mCRPC lines 1-4+)
`39.6%
`41.4%
`42.1%
`43.4%
`43.5%
`47.1%
`49.2%
`1st line mCRPC Share
`35.8%
`36.8%
`37.0%
`38.0%
`40.2%
`41.7%
`43.1%
`2nd line mCRPC Share
`34.5%
`33.5%
`32.6%
`33.5%
`32.9%
`28.9%
`26.5%
`Total Xtandi Share (mCRPC lines 1-4+)
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December)
`
`1st line mCRPC US Market Share (in patients)
`
`3Q16
`2Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`
`ZYTIGA
`41.2%
`39.6%
`41.4%
`42.1%
`43.4%
`43.5%
`47.1%
`49.2%
`Xtandi
`35.2%
`35.7%
`34.4%
`33.3%
`33.4%
`32.7%
`27.5%
`23.7%
`Docetaxel
`13.9%
`14.8%
`14.5%
`16.0%
`14.3%
`13.5%
`12.9%
`14.9%
`Other Chemo
`3.4%
`3.3%
`2.8%
`1.7%
`1.8%
`2.4%
`3.4%
`3.4%
`8.6%
`8.9%
`9.0%
`8.9%
`9.2%
`9.9%
`11.0%
`10.8%
`Other Hormone
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December). Share
`including all competitors exceeds 100% as a result of products being used in combination therapy
`
`3Q16
`33.4%
`41.2%
`37.1%
`33.2%
`
`4Q16
`33.9%
`42.0%
`38.2%
`31.2%
`
`4Q16
`
`42.0%
`34.2%
`14.3%
`3.1%
`8.5%
`
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`Monthly Patient Share: 1st Line mCRPC
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`
`Zytiga
`
`Xtandi
`
`Docetaxel
`
`Other Chemo
`
`Other Hormone
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16
`42%
`42%
`43%
`40%
`39%
`40%
`40%
`
`Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`40%
`41%
`42%
`41%
`42%
`43%
`
`33%
`
`16%
`
`2%
`
`9%
`
`35%
`
`14%
`
`2%
`
`9%
`
`34%
`
`14%
`
`3%
`
`9%
`
`34%
`
`15%
`
`4%
`
`9%
`
`36%
`
`15%
`
`3%
`
`9%
`
`35%
`
`15%
`
`3%
`
`9%
`
`35%
`
`15%
`
`3%
`
`9%
`
`35%
`
`14%
`
`3%
`
`9%
`
`35%
`
`14%
`
`3%
`
`9%
`
`35%
`
`14%
`
`4%
`
`8%
`
`35%
`
`14%
`
`3%
`
`9%
`
`33%
`
`15%
`
`3%
`
`9%
`
`35%
`
`14%
`
`3%
`
`8%
`
`
`
`
`
`2nd line mCRPC US Market Share (in patients)
`
`3Q16
`2Q16
`4Q16
`1Q16
`4Q15
`3Q15
`2Q15
`1Q15
`4Q14
`
`ZYTIGA
`38.2%
`37.1%
`35.8%
`36.8%
`37.0%
`38.0%
`40.2%
`41.7%
`43.1%
`Xtandi
`40.5%
`43.2%
`44.6%
`43.4%
`41.3%
`42.2%
`41.0%
`37.8%
`35.0%
`Docetaxel
`11.9%
`13.0%
`13.3%
`13.5%
`15.6%
`15.2%
`14.0%
`12.7%
`16.3%
`Other Chemo
`8.2%
`7.6%
`6.6%
`7.4%
`6.9%
`4.8%
`5.4%
`7.9%
`5.9%
`8.7%
`6.5%
`6.7%
`6.3%
`6.3%
`6.0%
`6.4%
`7.4%
`7.3%
`Other Hormone
`*4Q share reflects data through the fourth week of December (with projections made for the remaining one week of December).
`Share including all competitors exceeds 100% as a result of products being used in combination therapy
`
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`Monthly Patient Share: 2nd Line mCRPC
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`
`Zytiga
`
`Xtandi
`
`Docetaxel
`
`Other Chemo
`
`Other Hormone
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16
`36%
`37%
`38%
`36%
`36%
`35%
`36%
`
`Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`38%
`37%
`37%
`38%
`38%
`39%
`
`40%
`
`16%
`
`7%
`
`7%
`
`42%
`
`14%
`
`8%
`
`6%
`
`44%
`
`13%
`
`7%
`
`7%
`
`44%
`
`13%
`
`7%
`
`6%
`
`44%
`
`13%
`
`6%
`
`7%
`
`44%
`
`14%
`
`7%
`
`7%
`
`45%
`
`13%
`
`7%
`
`7%
`
`44%
`
`13%
`
`6%
`
`6%
`
`43%
`
`13%
`
`8%
`
`7%
`
`42%
`
`13%
`
`9%
`
`7%
`
`41%
`
`12%
`
`9%
`
`9%
`
`40%
`
`12%
`
`8%
`
`9%
`
`41%
`
`11%
`
`8%
`
`9%
`
`
`
`
`Total Zytiga (mCRPC)
` Zytiga 1st line mCRPC
` Zytiga 2nd line mCRPC
`Total Xtandi (mCRPC)
` Xtandi 1st line mCRPC
` Xtandi 2nd line mCRPC
`
`Full Year Historical Average Share (in patients):
`2014
`2015
`42.9%
`36.0%
`54.9%
`44.0%
`46.7%
`39.2%
`23.4%
`32.0%
`19.2%
`31.7%
`31.2%
`40.6%
`
`2016
`33.2%
`41.1%
`37.0%
`33.1%
`34.9%
`42.9%
`
`
`
`
`
`
`
`ACTIVE 220440902v.1
`
`

`

`
`
`
`
`Monthly Average Patient Share: Total mCRPC lines 1-4+ (excluding
`spontaneous use in non-metastatic and hormone sensitive patients)
`
`Monthly Patient Share: Total mCRPC
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`
`Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16
`33%
`33%
`34%
`33%
`32%
`32%
`32%
`
`Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16
`33%
`33%
`34%
`33%
`34%
`35%
`
`34%
`
`14%
`
`8%
`
`19%
`
`33%
`
`14%
`
`7%
`
`19%
`
`34%
`
`14%
`
`8%
`
`20%
`
`35%
`
`14%
`
`7%
`
`19%
`
`34%
`
`14%
`
`7%
`
`20%
`
`34%
`
`13%
`
`8%
`
`20%
`
`33%
`
`14%
`
`7%
`
`19%
`
`33%
`
`13%
`
`8%
`
`21%
`
`33%
`
`13%
`
`8%
`
`19%
`
`32%
`
`14%
`
`8%
`
`21%
`
`30%
`
`14%
`
`7%
`
`22%
`
`32%
`
`13%
`
`7%
`
`21%
`
`
`
`
`
`2014
`10,609
`2,843
`1,738
`15,189
`
`2013
`8,859
`2,334
`1,458
`12,651
`
`2015
`10,241
`2,799
`1,796
`14,836
`
`2016
`10,167
`2,395
`1,856
`14,417
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`Zytiga
`
`Xtandi
`
`Docetaxel
`
`Other Chemo
`
`32%
`
`16%
`
`8%
`
`Other Hormone
`
`19%
`
`
`
`
`Monthly Average
`ZYTIGA patients
`mCRPC
`nmCRPC
`All Other
`TOTAL
`
`
`
`ACTIVE 220440902v.1
`
`